期刊
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY
卷 62, 期 -, 页码 131-153出版社
ANNUAL REVIEWS
DOI: 10.1146/annurev-pharmtox-052220-015912
关键词
prostate cancer; androgen receptor; treatment resistance; therapies
资金
- Movember Foundation/Prostate Cancer UK
- US Department of Defense
- Prostate Cancer Foundation
- Stand Up To Cancer-Prostate Cancer Dream Team Translational Research Grant
- Cancer Research UK
- UK Department of Health through an Experimental Cancer Medicine Centre grant
- Wellcome Trust
In the last two decades, there has been significant progress in the treatment of advanced prostate cancer by targeting androgen and the androgen receptor (AR). However, drug resistance remains a challenge that needs to be addressed for the development of future therapeutic strategies.
Owing to the development of multiple novel therapies, there has been major progress in the treatment of advanced prostate cancer over the last two decades; however, the disease remains invariably fatal. Androgens and the androgen receptor (AR) play a critical role in prostate carcinogenesis, and targeting the AR signaling axis with abiraterone, enzalutamide, darolutamide, and apalutamide has improved outcomes for men with this lethal disease. Targeting the AR and elucidating mechanisms of resistance to these agents remain central to drug development efforts. This review provides an overview of the evolution and current approaches for targeting the AR in advanced prostate cancer. It describes the biology of AR signaling, explores AR-targeting resistance mechanisms, and discusses future perspectives and promising novel therapeutic strategies.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据